Skip to main content
Premium Trial:

Request an Annual Quote

NHGRI Adds IP-Management Guidelines to Genome Sequencing Center RFA

NEW YORK, March 27 (GenomeWeb News) - The National Human Genome Research Institute has amended a large-scale sequencing RFA that it issued in December to include guidelines for intellectual property related to the initiative.


In a notice issued Friday, NHGRI updated its previous "Genome Sequencing Centers" request for applications to include the stipulation that awardees manage IP and data in a way that will "maximize the public benefit of the data produced."


As a result, "applicants should develop a comprehensive IP and data management strategy that is consistent with the NIH Research Tools Policy," NIH said.


"Applicants should submit an IP Management Plan that assures that data is rapidly released according to approved criteria, that licensing and sharing practices ensure the availability of data and research resources for future use by the scientific community, and that research collaboration or sponsorship agreements are consistent with the requirements of the TCGA [The Cancer Genome Atlas] and the NHGRI medical sequencing program," NIH said in the notice.


Further details are available here.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.